Table 1 Clinicopathologic parameters affecting overall survival of patients with DLBCL (n = 110).
From: Stem cell characteristics promote aggressiveness of diffuse large B-cell lymphoma
Parameter | Worse factor | No. (%) | Uni | Multi | Hazard | 95% CI | |
|---|---|---|---|---|---|---|---|
(100%) | (p) | (p) | Ratio | Lower | Upper | ||
Sex | Male | 57 (52%) | 0.308 | - | |||
Age | > 60 years | 64 (58%) | 0.001 | 0.175 | 1.330 | 0.691 | 2.561 |
Site | Extranodal | 47 (43%) | 0.425 | - | |||
B symptoms | Present | 29 (26%) | 0.004 | 0.062 | 1.756 | 0.961 | 3.211 |
Phenotype | Activated B cell | 85 (77%) | 0.105 | - | |||
EBV | Present | 11 (10%) | 0.048 | - | |||
LDH | > 200 IU/L | 72 (65%) | 0.015 | - | |||
IPI score | 3–5 | 44 (40%) | < 0.001 | < 0.001 | 2.487 | 1.268 | 4.878 |
NANOG | Present | 12 (11%) | 0.009 | 0.066 | 1.798 | 0.963 | 3.357 |
HOXA9 | Present | 22 (20%) | 0.001 | 0.022 | 2.540 | 1.132 | 5.697 |
S100A8 | Present | 14 (13%) | 0.532 | - | |||
BMP8B | Present | 41 (37%) | 0.042 | - | |||
CCR6 | Present | 24 (22%) | 0.007 | 0.002 | 2.419 | 1.377 | 4.247 |
Stage | III-IV | 51 (46%) | 0.013 | - | |||
Treatment | Absent | 7 (6%) | < 0.001 | < 0.001 | 0.093 | 0.028 | 0.308 |
Bone marrow Involvement | Present | 23 (21%) | 0.013 | - | |||
Bcl-2 | Present | 73 (66%) | 0.077 | - | |||
BLS type | Present | 9 (8%) | < 0.001 | 0.018 | 2.695 | 1.183 | 6.138 |
